Quoin Pharmaceuticals. Ltd Sponsored ADR QNRX 深 沪
已收盘 04-02 16:00:00 美东时间
7.02
+0.960
+15.84%
华盛通- 最 高7.10
- 今 开5.8501
- 成交量 5.95万股
- 最 低 5.8501
- 昨 收 6.06
- 总市值 1266.15万
- 52周最高 41.80
- 市盈率 静 --
- 换手率 3.30%
- 52周最低 5.01
- 委 比 -3.85%
- 总股本 180.36万
- 历史最高 1417500.00
- 量 比 0.59
- 振 幅 20.63%
- 历史最低 5.824
- 每 手 1
- 风险率 3.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Kingswood Acquisition Corp. Class A涨59.20%，Enterprise Financial Services Corp Depositary Shs Repr 1/40th 5 % Non-Cum Red Perp Pfd Shs Series A涨27.12%
Kingswood Acquisition Corp. Class A涨59.20%；Enterprise Financial Services Corp Depositary Shs Repr 1/40th 5 % Non-Cum Red Perp Pfd Shs Series A涨27.12%；PMGC Holdings Inc.涨26.54%
04-01 13:01
美股夜盘 | 优品车涨40.80%，Globavend Holdings Ltd.涨40.78%
优品车涨40.80%；Globavend Holdings Ltd.涨40.78%；BeLive Holdings涨14.67%
03-27 15:01
美股夜盘 | 优品车涨45.22%，Globavend Holdings Ltd.涨42.72%
优品车涨45.22%；Globavend Holdings Ltd.涨42.72%；Turbo Energy涨12.76%
03-27 13:01
美股夜盘 | Globavend Holdings Ltd.涨49.51%，优品车涨42.80%
Globavend Holdings Ltd.涨49.51%；优品车涨42.80%；雷特控股涨18.88%
03-27 10:01
Quoin Pharmaceuticals Q4 EPS $(1.74) Beats $(4.02) Estimate
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of $(4.02) by 56.72 percent. This is a 85.96 percent increase over losses of $(12.39) per share
03-26 20:32
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
Quoin Pharma Provides Clinical And Regulatory Update From Recent Constructive Type C Meeting With FDA For QRX003, For Treatment Of Netherton Syndrome
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S.FDA expressed openness to an alternative study design for Phase 3 that would likely not include a traditional upfront
03-25 20:39
Quoin Pharmaceuticals Receives FDA's Fast Track Designation To QRX003 Lotion To Treat Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan
03-11 20:41
Quoin Pharmaceuticals Submits Orphan Drug Designation Application To Japan's MHLW For QRX003 To Treat Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that following a successful meeting with
01-27 21:37
Quoin Pharmaceuticals Submits Application For Breakthrough Medicine Designation With Saudi Food And Drug Authority For QRX003 To Treat Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has filed an application for
01-20 21:35
